MJPCFAI
VRTX icon

Michael J. Porro & Co. Financial Advisors, Inc.’s Vertex Pharmaceuticals VRTX Stock Holding History

Michael J. Porro & Co. Financial Advisors, Inc.’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.73M Buy
+3,818
New +$1.65M 1.45% 15

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Michael J. Porro & Co. Financial Advisors, Inc.'s VRTX Position: Q4 2025 in Review

Michael J. Porro & Co. Financial Advisors, Inc. opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2025: 3,818 shares worth $1.73M. The stake represents 1.45% of the portfolio and ranks #15 among its holdings.

1,674 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Michael J. Porro & Co. Financial Advisors, Inc. held 3,818 shares of Vertex Pharmaceuticals worth $1.73M as of Q4 2025.
  • Vertex Pharmaceuticals was a new Michael J. Porro & Co. Financial Advisors, Inc. position in Q4 2025.
  • Vertex Pharmaceuticals made up 1.45% of Michael J. Porro & Co. Financial Advisors, Inc.'s portfolio in Q4 2025, its #15 holding.
  • 1,674 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Michael J. Porro & Co. Financial Advisors, Inc.'s 13F filing for Q4 2025, filed 8 Oct 2026.